argenx’s (ARGX) Overweight Rating Reiterated at Piper Jaffray Companies
argenx (NASDAQ:ARGX)‘s stock had its “overweight” rating reaffirmed by investment analysts at Piper Jaffray Companies in a research note issued on Monday, The Fly reports. They currently have a $154.00 price target on the stock. Piper Jaffray Companies’ price target indicates a potential upside of 76.40% from the company’s current price.
ARGX has been the topic of several other reports. Nomura assumed coverage on argenx in a research note on Friday, June 29th. They issued a “buy” rating and a $161.00 target price on the stock. Wedbush lifted their target price on argenx from $93.00 to $114.00 and gave the company an “outperform” rating in a research note on Monday, June 25th. ValuEngine upgraded argenx from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. JMP Securities lifted their target price on argenx from $93.00 to $130.00 and gave the company a “positive” rating in a research note on Monday, June 18th. Finally, Cowen reiterated a “buy” rating on shares of argenx in a research note on Thursday, June 14th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. argenx presently has an average rating of “Buy” and a consensus price target of $133.43.
Shares of ARGX stock opened at $87.30 on Monday. argenx has a twelve month low of $21.25 and a twelve month high of $103.00. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -65.56 and a beta of 2.12.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.